Locally advanced gastric/gastroesophageal junction adenocarcinoma

Clinical trials for Locally advanced gastric/gastroesophageal junction adenocarcinoma explained in plain language.

Never miss a new study

Get alerted when new Locally advanced gastric/gastroesophageal junction adenocarcinoma trials appear

Sign up with your email to follow new studies for Locally advanced gastric/gastroesophageal junction adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 2 Not yet recruiting 1 Not yet finished but already full! 1

Promising drug duo targets Hard-to-Treat HER2 cancers

Disease control Not yet recruiting

This study tests two drugs, zanidatamab and tislelizumab, combined with standard chemo or radiation for people with HER2-positive stomach or colorectal cancers. About 70 adults aged 18-75 will receive the treatment to see if it shrinks tumors and controls the disease. The goal is…

Matched conditions: LOCALLY ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Phase 2 • Sponsor: Tao Zhang • Aim: Disease control

Last updated Jun 27, 2026 07:59 UTC

Locally advanced gastric/gastroesophageal junction adenocarcinoma

Get alerted when new Locally advanced gastric/gastroesophageal junction adenocarcinoma trials appear

Promising drug duo targets Hard-to-Treat HER2 cancers